We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

July 29, 2021

3 Big Little Things August 2021

Commentary
HealthXL Research Team

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar.


Prescription and DTx; the ensemble making headway

Expert: Chris Wasden, Head of DTx , Happify Health

Chris leads Happify's digital therapeutics effort to take its world-leading digital mental health and wellbeing platform to the pharmaceutical and healthcare industry. He also serves as a board member for the Digital Therapeutics Alliance. Connect with Chris to get his perspective on how digital therapeutics are shaping the future of mental health and psychiatric care. https://www.linkedin.com/in/chriswasden/ 


Snapshot of the story

This month, digital therapeutics (DTx) company Happify Health announced their first prescription DTx to treat patients with both major depressive disorder (MDD) and generalized anxiety disorder (GAD). The therapy, dubbed Ensemble, includes a 10-week cognitive behavioral therapy (CBT) program to help teach patients how to change negative thought patterns. It also includes a dashboard doctors can use to monitor patients. It is the first transdiagnostic PDT for MDD and GAD available in the U.S. 


Why is it notable:

 

Industry Implications:

Read the full story here.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Evidence, behaviours and outcomes; capturing the real-world

Expert: Paul Feldheausen, Director Of Strategic Partnerships, Holmusk

Paul is the Director of Growth Operations & Partnerships at Holmusk, where he is working to build the world's largest real-world evidence platform for behavioral health and chronic diseases. He has extensive expertise in leading complex health engagements in the US and Asia, and over the past 15 years Paul has worked to drive behavioral and structural changes in the way patients interact and participate within the health ecosystems. Connect with Paul to get his perspective on leveraging real-world data for improving outcomes.

https://www.linkedin.com/in/paul-feldhausen/ 


Snapshot of the story

This week Otsuka announced the signing of a three-year collaboration with global data science company Holmusk to enhance digital health and data analytics for global behavioral health programs. One of Holmusk’s main focuses is on building a real-world evidence (RWE) platform for behavioral health. Together, Otsuka and Holmusk will work to drive a deeper understanding of unmet patient needs and real-world outcomes by employing proprietary analytics and artificial intelligence (AI) on multiple real-world data sources. 


Why it is notable

 

Industry Implications

Read the full story here.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Blending physical, virtual, and automated care; the new telenormal

Expert: Murray Brozinskly, Conversa Health

Murray is a creative entrepreneur who has started, run, and served as a senior executive at numerous companies. He has extensive experience in leadership, strategy, bringing new products to market, generating revenue, building strategic relationships, as well as M&A. In addition to working as a digital health leader in automated care management at Conversa Health he works as a Board member and advisor to other promising technology start-ups in various industries. Connect with Murray to get his perspective on how M&As will shape the strategy of telemedicine companies in the future. https://www.linkedin.com/in/murraybrozinsky/ 


Snapshot of the story 

This week telehealth giant Amwell announced the acquisition of SilverCloud Health and Conversa Health in a bid to enhance its virtual care platform. Their acquisition will broaden Amwells offersings differentiating it among competitors. We are super proud of our friends at Conversa Health & Silvercloud Health on this milestone!'. Covid-19 has cut through the red tape that initially restricted telehealth adoption, forcing the healthcare world to do a 180° on digital health, and these acquisitions offer a clear example to how telehealth is innovatively responding.


Why is it notable:



Industry Implications

Read the full story here.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

No upcoming Virtual Events scheduled. Please check back again soon.

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

19th March 2024 @ 12pm ET

Emerging Trends: Decentralised to Home-based Clinical Trials

The landscape of cancer care is evolving, with startups changing the field by bringing care to patients' homes.

Hansa Bhargava
Featuring
Hansa Bhargava
Chief Clinical Strategy and Innovation Officer, Healio
20th March 2024 @ 12pm ET

Exploring Gen AI in the Pharmaceutical Industry

Gen AI in pharma is an emerging field that leverages AI to enhance various aspects of the pharmaceutical industry.

Dave Peak
Featuring
Dave Peak
Advisor, Independent
21st March 2024 @ 12pm ET

Unlocking AI's Potential in Medical Affairs

AI has significant potential to unlock new opportunities in medical affairs within the pharma industry.

Robert Stevens
Featuring
Robert Stevens
Principal, RS CONSULTATIVE, LLC
26th March 2024 @ 12pm ET

Managing Risks and Maximising ROI Strategies

Managing risks and maximising ROI is the new mantra of digital health investors.

Adam Kaufman
Featuring
Adam Kaufman
Senior Advisor, EVERSANA

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.